Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial

J Orthop Surg Res. 2020 Jan 16;15(1):17. doi: 10.1186/s13018-020-1547-5.

Abstract

Background: Stress shielding after total hip arthroplasty (THA) can induce bone mineral density (BMD) loss around the femoral implant. Several studies using drug have described methods to prevent BMD loss around implants following THA. Switching from teriparatide to alendronate was reported to increase lumbar BMD; on the other hands, it is unclear whether switching from teriparatide to alendronate is effective around the implant. The aim of this study is that changes in BMD is compared in patients switched from teriparatide to alendronate, in patients treated with alendronate alone, and in control patients without medication after total hip arthroplasty.

Patients and methods: Patients were randomized into three groups, those switched to alendronate after teriparatide (switch: n = 17), those receiving continuous alendronate (ALD: n = 15), and control untreated patients (control: n = 16) and followed up for 2 years after THA. Baseline periprosthetic BMD was measured by dual-energy X-ray absorptiometry (DEXA) 1 week after THA, followed by subsequent measurements at 1 and 2 years postoperatively. Lumbar BMD was also evaluated at preoperatively, 1 and 2 years postoperatively.

Results: Two years after surgery, BMD (%) at zone 1 was significantly higher in the switch group than in the control group (P = 0.02). BMD (%) at zone 7 was significantly higher in the switch and ALD groups than in the control group (P = 0.01, P = 0.03). Lumbar BMD (%) anterior-posterior (AP) side was significantly higher in the switch group than in the ALD and control groups 2 years after surgery. On the other hand, lumbar BMD (%) lateral side was significantly higher in the switch and ALD groups than control group 2 years after surgery.

Conclusions: Switching therapy had a significant effect on BMD of the lumbar spine and zones 1 and 7 at 2 years postoperatively. At zone 1 in particular, it was found to be more effective than ALD alone.

Trial registration: UMIN, registry number UMIN000016158. Registered 8 January 2015.

Keywords: Alendronate (ALD); Bone mineral density (BMD); Teriparatide; Total hip arthroplasty (THA).

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Alendronate / administration & dosage*
  • Arthroplasty, Replacement, Hip / adverse effects
  • Bone Density / drug effects*
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Resorption / etiology
  • Bone Resorption / prevention & control*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Postoperative Complications / etiology
  • Postoperative Complications / prevention & control*
  • Teriparatide / administration & dosage*

Substances

  • Bone Density Conservation Agents
  • Teriparatide
  • Alendronate